Subjects

Evidence, safety and regulatory analysis of CJC-1295.

Mechanism, human studies and safety information on Ipamorelin.

Sermorelin evidence, approval history and comparison articles.

GHRP-6 mechanism, metabolic effects and evidence.

Articles centered on human clinical and pharmacology studies.

Safety signals and evidence gaps involving the GH and IGF-1 axis.

Approval, compounding and regulatory status of GH-axis compounds.

Current anti-doping rules for CJC-1295 and related compounds.

Evidence-based comparisons of GHRH analogues and growth hormone secretagogues.

GHRH, GH, IGF-1 and ghrelin receptor fundamentals.

Evidence reviews distinguishing short-acting Modified GRF (1-29), often marketed as CJC-1295 no DAC, from CJC-1295 with DAC.

Human-study, mechanism, safety and regulatory reviews of hexarelin.

Structured reviews of registered and published human studies involving GH-axis peptides.

Educational reviews of U.S. compounding policy, identity, quality and regulatory evidence.